TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,886 | -23.8% | 7,929 | +31.0% | 0.00% | -33.3% |
| Q2 2023 | $92,974 | +130849.3% | 6,053 | +92.8% | 0.00% | +50.0% |
| Q1 2023 | $71 | -36.6% | 3,139 | -41.2% | 0.00% | -60.0% |
| Q4 2022 | $112 | -99.9% | 5,336 | -34.1% | 0.01% | +66.7% |
| Q3 2022 | $199,000 | -58.6% | 8,099 | -59.2% | 0.00% | -72.7% |
| Q2 2022 | $481,000 | +74.9% | 19,861 | +85.8% | 0.01% | +266.7% |
| Q1 2022 | $275,000 | +21.7% | 10,690 | +46.4% | 0.00% | -25.0% |
| Q4 2021 | $226,000 | +69.9% | 7,301 | +33.3% | 0.00% | +33.3% |
| Q3 2021 | $133,000 | +84.7% | 5,479 | +10.6% | 0.00% | +50.0% |
| Q2 2021 | $72,000 | +22.0% | 4,956 | +110.9% | 0.00% | +100.0% |
| Q1 2021 | $59,000 | +40.5% | 2,350 | +51.5% | 0.00% | 0.0% |
| Q4 2020 | $42,000 | – | 1,551 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |